

- Lung(s) (*Continued*)  
 epidemiology of, 266, 266.e1f  
 pathology of, 266  
 prognosis of, 270  
 staging systems, 269t  
 treatment for, 268-270  
 perfusion of, 196, 196f  
 physiology of. *see* Respiratory physiology  
 respiratory zone of, 191  
 toxin, irritant, allergen exposure of, 187
- Lung biopsy, 188  
 in immunocompromised host, 949f
- Lung cancer, 592-597  
 clinical presentation of, 595, 595.e1f  
 definition of, 592  
 diagnosis and differential diagnosis of, 595-596  
 epidemiology of, 592  
 genome of, 594-595  
 histologic subgroups of, 592-593  
 hypertrophic osteoarthropathy in, 813-814  
 management of, tyrosine kinase inhibitors in, 590t  
 mediastinal adenopathy and, 251  
 molecular-genomic subtypes of, 593-594, 594t  
 non-small cell, 592  
 paraneoplastic syndromes associated with, 593t  
 pathology of, 592-595  
 positron emission tomography of, 205  
 prognosis of, 597  
 screening for, 596  
 small cell, 593, 592.e1f, 593.e1f  
 staging of, 595, 596t  
 treatment for, 596-597
- Lung injury, acute, 262-263  
 in idiopathic pulmonary fibrosis, 227
- Lung transplantation  
 in idiopathic pulmonary fibrosis, 227  
 for interstitial lung disease, in systemic sclerosis, 792  
 progressive bronchiolitis obliterans, 216  
 with pulmonary dysfunction, 237  
 for pulmonary hypertension, arterial, 164
- Lung volume reduction surgery (LVRS), 214-215
- Lung volumes  
 allergens affecting, 187  
 in interstitial lung disease, 224f  
 measurements of, 188, 200, 201f-202f  
 in obstructive lung disease, 212
- Lupus anticoagulant, 568, 785  
 diagnosis of, 545  
 digital ulcerations associated with, 791  
 thrombocytopenia with, 551  
 as work-up for venous thromboembolism, 570-571
- Lupus arthritis, in systemic lupus erythematosus, 780
- Lupus-like syndrome, 814
- Lupus nephritis, 321-322, 781  
 classification of, 322t, 323f
- Lupus pernio, 230
- Luteal phase, of menstrual cycle, 698-699
- Luteinizing hormone (LH), 624, 625t-626t, 631, 652, 652f  
 in male, 714
- Luteinizing hormone-releasing hormone (LHRH)  
 agonists  
 for prostate cancer, 588, 607
- Lyme disease, 843  
 meningitis and, 855
- Lymph node biopsy, 523
- Lymph nodes, 521, 521f  
 enlargement of, 267, 267.e1f  
 lung cancer and, 595, 595.e1f
- Lymphadenopathy  
 causes of, 523, 523t  
 cervical, 523  
 fever with, 843-844  
 regional, infections causing, 844  
 in tuberculosis, 256
- Lymphangiomyomatosis, 237
- Lymphatic filariasis (elephantiasis), 956
- Lymphoblastic leukemia, acute, 496t-497t, 499-500
- Lymphoblastic lymphoma, 526
- Lymphocytes, 479  
 autoreactive, aplastic anemia and, 482-483  
 congenital and acquired disorders of, 533  
 development, function, and localization of, 520-522  
 disorders of, 520-533
- Lymphocytic gastritis, 413
- Lymphocytic thyroiditis. *see* Hashimoto's thyroiditis.
- Lymphocytosis, 517  
 reactive, 528-529
- Lymphogranuloma venereum, 844
- Lymphoid follicles, 521
- Lymphoid neoplasms, classification of, 522t
- Lymphoid origin, neoplasia of, 522-533
- Lymphoid system, 521-522
- Lymphoma. *see also* Mucosa-associated lymphoid tissue (MALT).  
 central nervous system, in HIV-infected patients, 939  
 gastric, 405  
 Mediterranean, 532  
 post-transplantation lymphoproliferative disorder, 533  
 rheumatic manifestations of, 818  
 staging evaluation for, 524t  
 staging system, 524t  
 subtypes, 524-526
- Lymphoproliferative disease, in Sjögren's syndrome, 818
- Lynch syndrome, 577, 601
- Lysergic acid diethylamide (LSD), 1129t-1130t, 1136
- M**
- M. pneumoniae*, 255
- M-CSF (macrophage colony-stimulating factor), 517
- M proteins, 529-530, 530t
- Machinery murmurs, 34-35
- Macro-reentrant atrial tachycardia, 124-125
- Macrocytic anemia, 505-507
- Macrophage colony-stimulating factor (M-CSF), 517
- Macrophages, 517  
 fever and, 835  
 properties and function of, 825
- Macula densa, 284-285
- Magnesium  
 deficiency of, 739  
 causes of, 740  
 symptoms of, 739  
 excessive renal losses of, 749  
 inadequate intake of, 749  
 intestinal absorption of, 739  
 for migraine prevention, 996  
 serum, regulation of, 739-740
- Magnesium sulfate, in preeclampsia, 347
- Magnetic resonance angiography (MRA)  
 in deep vein thrombosis, 165  
 in mesenteric ischemia, 394, 394f  
 in peripheral arterial disease, 159-160  
 for renal artery stenosis, 343
- Magnetic resonance cholangiopancreatography (MRCP), 394, 394f, 472  
 in chronic pancreatitis, 434
- Magnetic resonance enterography, 421
- Magnetic resonance imaging (MRI), 51, 51f, 268  
 of abdomen and pelvis, 394  
 for acute lower back pain, 1001  
 in acute pancreatitis, 428  
 of anterior pituitary, 624  
 in aortic coarctation, 71  
 for appendicitis, 893  
 of brain abscess, 862, 862f  
 of brain tumors, 1065  
 cardiac, in pulmonary valve disease, 85  
 in chronic kidney disease, 297  
 in Creutzfeldt-Jakob disease, 866  
 in epilepsy, 1057-1058  
 for infective endocarditis, 880  
 in multiple sclerosis, 1070, 1071f  
 of musculoskeletal disease, 769  
 for neural tube disorders, 1027  
 in neurologic disease, 964  
 in pericardial effusions, 137-138  
 of pituitary adenoma, 649  
 in respiratory disorders, 204-205  
 of spinal epidural abscess, 864, 864f  
 for stress testing, 93  
 in stroke, 1039, 1040f  
 of subdural empyema, 863  
 in tetralogy of Fallot, 73, 74f  
 in transposition of great arteries, 75  
 vs. computed tomography, 964t
- Maintenance of wakefulness test (MWT), 971
- Major histocompatibility complex (MHC)  
 proteins. *see also* Human leukocyte antigen (HLA).  
 stem cell transplantation and, 481
- Malabsorption, 378-384  
 in chronic pancreatitis, 434  
 clinical presentation of, 380  
 definition of, 378  
 diagnosis of, 380-383, 381f  
 epidemiology of, 378  
 fecal fat analysis for, 380-381  
 imaging studies in, 381-382  
 in inflammatory bowel disease, 419  
 luminal phase and, 379